Best Life Sciences Companies To Watch In Right Now

Today, central banks are acting more aggressively than ever before to stave off deflation and spur global growth. The European Central Bank, the People’s Bank of China, the Bank of Japan, the Bank of England and the Federal Reserve have all embarked on quantitative easing (QE) programs following the 2008 financial crisis.

See Also: Kiplinger’s Economic Outlook on Interest Rates

QE has pushed interest rates down around the world and is forcing investors to get creative as they search for yield. Traditionally, clients have relied on a combination of Social Security benefits, pension income and interest from a conservative fixed income portfolio to support them in retirement. Even as the Fed makes moves to slowly increase rates, while they’re so low, you must decide whether to: (a) reduce your living expenses; (b) take on more credit risk by purchasing lower quality, higher yielding investments; or (c) increase your allocation to dividend-paying equities to meet your cash flow needs. The further out you go on the risk spectrum, the higher the potential volatility and risk of loss.

Best Life Sciences Companies To Watch In Right Now: Portola Pharmaceuticals, Inc.(PTLA)

 

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The companys other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lees Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. Portola Pharmaceuticals, Inc. has a collaboration with Bristol-Myers Squibb and Pfizer Inc. to develop and commercialize apixaban, an oral anticoagulant. The company was founded in 2003 and is headquartered in South San Francisco, California.

Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

Best Life Sciences Companies To Watch In Right Now: Diamondrock Hospitality Company(DRH)

DiamondRock Hospitality Company, incorporated on May 6, 2004, is a lodging-focused Maryland corporation operating as a real estate investment trust (REIT). The Company owns a portfolio of approximately 30 hotels and resorts throughout North America and the United States Virgin Islands that consists of over 10,925 guest rooms. Its primary business is to acquire, own, asset manage and renovate full-service hotel properties in the United States. Its portfolio is concentrated in gateway cities and destination resort locations. The Company conducts its business through an umbrella partnership REIT (UPREIT) in which the Company’s hotels are owned by subsidiaries of its operating partnership, DiamondRock Hospitality Limited Partnership. The Company is the sole general partner of its operating partnership and owns either directly or indirectly, all of the limited partnership units of its operating partnership. The Company leases all of its domestic hotels to taxable REIT subsidiar y (TRS) lessees. In turn, the Company’s TRS lessees must engage a third-party management company to manage the hotels. Each of its hotels is managed by a third party and a number of its hotels are operated under a brand owned by lodging brand companies, such as Marriott International, Inc. (Marriott), Starwood Hotels & Resorts Worldwide, Inc. (Starwood) and Hilton Worldwide (Hilton).

The Company’s owned hotel properties include Chicago Marriott, Hilton Minneapolis, Westin Boston Waterfront Hotel, Lexington Hotel New York, Salt Lake City Marriott Downtown, Renaissance Worthington, Frenchman’s Reef & Morning Star Marriott Beach Resort, Orlando Airport Marriott, Westin San Diego, Westin Fort Lauderdale Beach Resort , Westin Washington, D.C. City Center, Hilton Boston Downtown, Vail Marriott Mountain Resort & Spa, Marriott Atlanta Alpharetta, Courtyard Manhattan/Midtown East, Hilton Garden Inn Times Square Central, Bethesda Marriott Suites, Hilton Burlington, JW Mar riott Denver at Cherry Creek, Courtyard Manhattan/Fifth Aven! ue, The Lodge at Sonoma, a Renaissance Resort & Spa, Courtyard Denver Downtown, Hilton Garden Inn Chelsea/New York City, Renaissance Charleston, Inn at Key West and Hotel Rex.

The Company competes with Airbnb.

Advisors’ Opinion:

  • [By Monica Gerson]

    DiamondRock Hospitality Company (NYSE: DRH) is projected to post its quarterly earnings at $0.18 per share on revenue of $218.42 million.

    Weyerhaeuser Co (NYSE: WY) is expected to report its quarterly earnings at $0.20 per share.

Best European Companies To Buy Right Now: QC Holdings Inc.(QCCO)

QC Holdings, Inc. provides various retail consumer financial products and services in the United States. The company offers payday loans that provide cash to the customers in exchange for a promissory note with a maturity of two to three weeks. It also provides financial products and services, such as installment loans, credit services, check cashing services, title loans, money transfers, and money orders. In addition, QC Holdings operates as a credit services organization that arranges a third-party lender to make a loan to the consumer and for providing related services to the consumer, including a guarantee of the consumer?s obligation to the third-party lender. Further, the company sells used vehicles and earns finance charges from the related vehicle financing contracts; and provides reconditioning services on its inventory of vehicles, and repair services for its customers. As of As of December 31, 2010, the company operated 523 short-term lending branches in 24 sta tes; and 5 buy here, pay here lots located in Missouri and Kansas. QC Holdings, Inc. was founded in 1984 and is headquartered in Overland Park, Kansas.

Advisors’ Opinion:

  • [By Monica Gerson]

    QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings’ trailing-twelve-month profit margin is 0.60%.

    NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

Best Life Sciences Companies To Watch In Right Now: Church & Dwight Company, Inc.(CHD)

 

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products in the United States. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division (SPD). The Consumer Domestic segment offers household products, such as baking soda, carpet and cat litter deodorizers, clumping cat litters, washing soda, fabric softeners, daily shower cleaners, cleaning products, dishwashing detergents and boosters, laundry and cleaning solutions, and bathroom cleaners, as well as powder, liquid, and unit dose laundry detergents; and personal care products comprising toothpastes and oral rinses, home pregnancy and ovulation test kits, deodorants and antiperspirants, toothbrushes, shampoos, dietary supplements, depilatories, lotions, creams, waxes, oral analgesics, nasal saline moisturizers, and feminine hygiene products, as well as condoms, lubricants , and vibrating products. The Consumer International segment sells personal care, household, and over-the-counter products in international markets, such as Canada, France, Australia, China, the United Kingdom, Mexico, and Brazil. The SPD segment offers animal nutrition products, including feed grade sodium bicarbonate, rumen fermentation enhancers, feed grade potassium carbonate, rumen bypass fat and lysine, omega 3 and 6 essential fatty acids, natural sodium sesquicarbonate, and refined functional carbohydrate; and specialty chemicals, such as performance grade sodium bicarbonate, and potassium carbonate and bicarbonate. It also provides specialty cleaners, such as aqueous cleaners and deodorizers for commercial and industrial applications. The company sells its products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and pet stores, and other specialty stores, as well as through Websites. Church & Dwight Co., Inc. was founded in 1846 and is headquartered in Ewing, New ! Jersey.

Advisors’ Opinion:

  • [By Monica Gerson]

    Church & Dwight Co., Inc. (NYSE: CHD) shares rose 7.32 percent to $104.10 in pre-market trading. Negocios.com reported that Reckitt Benckiser will offer $23 billion for Church & Dwight.

  • [By Wayne Duggan]

    U.S. retailers performed poorly during the Christmas holiday season, but companies in the Valentine’s Day business are hoping that Americans will spend generously in the name of love this year. These names include flower delivery company 1-800-Flowers.Com Inc (NASDAQ: FLWS), L Brands Inc (NYSE: LB) (owner of both Victoria’s Secret and Bath & Body Works), Church & Dwight Co., Inc. (NYSE: CHD) (owner of Trojan brand condoms), candy giant Hershey Co (NYSE: HSY) and luxury jeweler Tiffany & Co. (NYSE: TIF).

  • [By Ben Levisohn]

    Remember when companies used to split their stock to keep individual shares affordable? No longer. Credit Suisse strategistsAna Avramovic andVictor Lin note that Church & Dwight (CHD) upcoming stock split will be just the fourth by an S&P 500 stock this year:

  • [By Shauna O’Brien]

    Deutsche Bank announced on Tuesday that it has upgraded Church & Dwight Co., Inc. (CHD).

    The firm has raised its rating on CHD from “Hold” to “Buy,” and has increased the company’s price target from $64 to $66. This price target suggests an 8% upside from the stock’s current price of $60.36.

    Analyst Bill Schmitz commented: “Sustainable growth algorithm of 3-4% organic sales, high single digit EBIT and double-digit EPS growth intact, with upside from fast growing Avid vitamin business joining the base and highly flexible balance sheet enabling further M&A or more aggressive cash flow redeployment providing upside to total shareholder return profile.

    “With shares underperforming the group and market over the last year and tempered Street outlook for CY14 versus long-term trend, we see an opportunistic window to own the shares at a reasonable entry point.”

    Church & Dwight shares were mostly flat during pre-market trading Tuesday. The stock is up 13% YTD.

Best Life Sciences Companies To Watch In Right Now: Heartware International, Inc.(HTWR)

Heartware International, Inc., incorporated on June 29, 2008, is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart.

The HeartWare HVAD System

The HVAD System consists of HVAD pump, a permanently implantable VAD, patient accessories and surgical tools. The HVAD pump is capable of generatin g over 10 liters of blood flow per minute. With a displaced volume of approximately 50 cubic centimeters and a mass of over 140 grams, the HVAD pump is implantable in the pericardial space, directly adjacent to the heart. The pump’s inflow cannula is integrated with the device itself, providing proximity between the heart and the pumping mechanism, facilitating ease of implant and helping to ensure optimal blood flow characteristics. The use of a wide-bladed impeller and the clear flow paths through the pump are designed to help reduce the risk of pump-induced damage to blood cells.

The HeartWare MVAD System

The MVAD System consists of similar components, surgical tools and peripherals, as the HVAD System, but is differentiated by the MVAD pump. The MVAD pump is a miniaturized blood pump intended for patients with chronic heart failure. The device is a full-output axial-flow pump with a fully suspended rotor and a displacement volume of less than on e-half of that of the HVAD pump.

The CircuLite ! System

The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass. The CircuLite Circulatory Support System offers interventional options to earlier-stage heart failure patients.

The Company competes with St. Jude Medical, Inc., Jarvik Heart, Inc., ReliantHeart Inc., Berlin Heart GmbH and Sunshine Heart, Inc.

Advisors’ Opinion:

  • [By Spencer Israel]

    4. HeartWare International Inc (NASDAQ: HTWR) – The heart device maker agreed to be acquired by Medtronic for $58 per share in cash two weeks ago. Prior to that the stock had been trading just above $30.